Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know

19.04.24 23:50 Uhr

Werte in diesem Artikel
Aktien

62,40 EUR -0,03 EUR -0,05%

Indizes

PKT PKT

18.674,2 PKT 128,0 PKT 0,69%

16.794,9 PKT 108,9 PKT 0,65%

2.525,7 PKT 3,1 PKT 0,12%

1.854,4 PKT -8,4 PKT -0,45%

5.308,1 PKT 4,9 PKT 0,09%

Gilead Sciences (GILD) closed at $66.76 in the latest trading session, marking a +0.91% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.88% for the day. Meanwhile, the Dow gained 0.56%, and the Nasdaq, a tech-heavy index, lost 2.05%.Shares of the HIV and hepatitis C drugmaker witnessed a loss of 9.48% over the previous month, trailing the performance of the Medical sector with its loss of 6.4% and the S&P 500's loss of 2.57%.The investment community will be closely monitoring the performance of Gilead Sciences in its forthcoming earnings report. The company is scheduled to release its earnings on April 25, 2024. The company is forecasted to report an EPS of $1.03, showcasing a 24.82% downward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $6.34 billion, showing a 0.15% drop compared to the year-ago quarter.Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $6.55 per share and revenue of $27.49 billion. These totals would mark changes of -2.53% and +1.37%, respectively, from last year.Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Gilead Sciences. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 7.41% fall in the Zacks Consensus EPS estimate. Gilead Sciences is currently a Zacks Rank #3 (Hold).Digging into valuation, Gilead Sciences currently has a Forward P/E ratio of 10.1. Its industry sports an average Forward P/E of 22.02, so one might conclude that Gilead Sciences is trading at a discount comparatively.Investors should also note that GILD has a PEG ratio of 0.91 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. GILD's industry had an average PEG ratio of 1.65 as of yesterday's close.The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 84, which puts it in the top 34% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.Top 5 Dividend Stocks for Your RetirementZacks targets 5 well-established companies with solid fundamentals and a history of raising dividends. More importantly, they have the resources and will to likely pay them in the future.Click now for a Special Report packed with unconventional wisdom and insights you simply won’t get from your neighborhood financial planner.See our Top 5 now – the report is FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Gilead Sciences

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Gilead Sciences

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu Gilead Sciences Inc.

Analysen zu Gilead Sciences Inc.

DatumRatingAnalyst
15.06.2020Gilead Sciences kaufenDZ BANK
15.03.2019Gilead Sciences OutperformBMO Capital Markets
03.01.2019Gilead Sciences OutperformOppenheimer & Co. Inc.
26.10.2018Gilead Sciences OverweightBarclays Capital
01.10.2018Gilead Sciences OverweightCantor Fitzgerald
DatumRatingAnalyst
15.06.2020Gilead Sciences kaufenDZ BANK
15.03.2019Gilead Sciences OutperformBMO Capital Markets
03.01.2019Gilead Sciences OutperformOppenheimer & Co. Inc.
26.10.2018Gilead Sciences OverweightBarclays Capital
01.10.2018Gilead Sciences OverweightCantor Fitzgerald
DatumRatingAnalyst
26.07.2018Gilead Sciences NeutralRobert W. Baird & Co. Incorporated
05.10.2017Gilead Sciences PerformOppenheimer & Co. Inc.
09.03.2017Gilead Sciences NeutralUBS AG
29.04.2016Gilead Sciences HoldMaxim Group
14.12.2012Gilead Sciences neutralGoldman Sachs Group Inc.
DatumRatingAnalyst
25.06.2010Gilead Sciences ausgestopptDer Aktionär
22.10.2009Gilead Sciences underperformWedbush Morgan Securities Inc.
10.02.2006Gilead Sciences underweightPrudential Financial
06.12.2005Gilead Sciences underweightPrudential Financial

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Gilead Sciences Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"